Sanofi-Aventis Sues Apotex Over ANDA For Eloxatin

By Jocelyn Allison

Law360, New York (August 29, 2008, 12:00 AM ET) -- Sanofi-Aventis has targeted Canada's Apotex Corp. in its latest effort to keep a generic version of colon cancer drug Eloxatin off the market in the United States.

In a complaint filed Wednesday in the U.S. District Court for the District of New Jersey, the French drugmaker claims Apotex's abbreviated new drug application with the U.S. Food and Drug Administration to make generic Eloxatin constitutes infringement of U.S. Patent Number 5,338,874.

The '874 patent is listed in the FDA's Orange Book for Eloxatin. Sanofi-Aventis licenses the patent...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles